Economic burden of hepatitis C‐associated diseases in the United States

@article{ElKhoury2012EconomicBO,
  title={Economic burden of hepatitis C‐associated diseases in the United States},
  author={Antoine C. El Khoury and William K. Klimack and Carolyn Wallace and Homie Razavi},
  journal={Journal of Viral Hepatitis},
  year={2012},
  volume={19}
}
Summary.  There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data sources for hepatitis C in the United States. A systematic literature search was conducted to identify studies reporting the costs of hepatitis C sequelae in the… Expand
Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas
TLDR
Knowing the burden of hepatitis C sequelae is useful for policy decisions as well as serving as a basis for determining the value of HCV screening and treatment. Expand
The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia.
TLDR
Findings from this review identified early detection as the first line of a preventive strategy to help reduce the evolving epidemic and that oral medications could reduce the risk of liver cancer and death. Expand
Economic Burden of Hepatitis C Infection.
TLDR
The economic burden of chronic hepatitis C might exceed $10 billion annually in the United States alone, and recent emergence of treatment options that are not only highly effective and safe but also costly has emphasized the need to study the disease from the economic point of view. Expand
Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy
TLDR
The clinical and economic burden of EHMs is substantial and can be reduced through viral eradication, especially if treatment is initiated early and not delayed until fibrosis advances, as well as within 3 to 6 years by savings in all‐cause medical costs. Expand
Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
TLDR
This analysis demonstrates that US HCV prevalence is in decline due to a lower incidence of infections, however, the prevalence of advanced liver disease will continue to increase as well as the corresponding healthcare costs. Expand
Health Affairs Capacity Is A Concern Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains , But Dieterich and
Treatment of hepatitis C virus, the most common chronic viral infection in the United States, has historically suffered from challenges including serious side effects, low efficacy, and ongoingExpand
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
TLDR
Without large screening programs, elimination of HCV cannot be achieved and the HCV elimination strategy is feasible and cost-saving despite the uncertainty of the future cost of DAAs in Greece. Expand
Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.
TLDR
Treating patients at all disease stages could generate $610-$1,221 billion in additional quality-adjusted life-years, plus an additional $139 billion in saved medical expenditures over fifty years, and minimize the disease burden, but up-front treatment costs would exceed $150 billion. Expand
Non-healthcare costs of hepatitis C: a systematic review
TLDR
There is an increasing interest in the indirect (or non- healthcare) costs of hepatitis C virus (HCV) and there is a need for studies addressing non-healthcare costs of HCV in settings where new treatments with DAAs have been implemented, as they are probably changing the current and future burden of the disease. Expand
Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan
TLDR
Treatment of HCV GT1b with all‐oral direct‐acting anti‐virals in Japan can lead to significant direct and indirect savings related to avoidance of HCC and DCC. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
Estimating future hepatitis C morbidity, mortality, and costs in the United States.
TLDR
The results confirm prior Centers for Disease Control and Prevention projections and suggest that HCV may lead to a substantial health and economic burden over the next 10 to 20 years. Expand
The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period.
TLDR
To date, pediatric HCV has received relatively little attention, but it will have a significant economic impact over the next 10 years if changes in practice are not made. Expand
Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C
TLDR
A decision analytic model was developed to project the immediate responses to treatment and predict the long-term outcomes on the basis of current natural history data to determine whether treatment of histologically mild chronic hepatitis C with a single 6-month course of interferon-2b would affect life expectancy and lifelong costs. Expand
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
TLDR
Routine liver biopsy before treatment with interferon increases the cost of managing patients with CHC without improving health outcomes, and quantitative HCV RNA testing to guide therapy misses some potential sustained responders. Expand
The burden of hepatitis C in the United States
TLDR
Future projections predict a 4‐fold increase between 1990 and 2015 in persons at risk of chronic liver disease (i.e., those with infection for 20 years or longer), suggesting a continued rise in the burden of HCV in the United States in the foreseeable future. Expand
Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C
TLDR
The cost-effectiveness of interferon- treatment from the point of view of society was assessed by comparing the number of liver-related deaths, quality-adjusted survival, and costs among the treatment strategies. Expand
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
TLDR
While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions. Expand
Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population
TLDR
Estimating all-cause and disease-related resource utilization and costs among managed care enrollees with chronic hepatitis C virus (HCV) found chronic HCV is a costly disease to managed care organizations and increased efforts in HCV screening and early treatment may lead to long-term cost savings. Expand
Projecting future complications of chronic hepatitis C in the United States
  • G. Davis, J. Albright, S. Cook, D. Rosenberg
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
TLDR
The prevalence of cirrhosis and the incidence of its complications will increase over the next 10 to 20 years, because the duration of infection increases among those with chronic hepatitis C. Expand
Hepatitis C and injecting drug use: impact, costs and policy options.
TLDR
Analysis of the impact and costs of hepatitis C among injecting drug users are presented, as a basis for sound policy-making, and issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy. Expand
...
1
2
3
4
5
...